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ABSTRACT
Atrial fibrillation (AF) is an important cause of
preventable, disabling stroke and is increasingly
prevalent with advancing age. As life
expectancies increase around the world, AF-
related stroke is a growing global public health
concern. Most AF patients are elderly (C75 years
old) and increasing age is a consistent
independent risk factor for AF-associated
stroke. Warfarin anticoagulation is highly
effective for stroke prevention in AF patients,
but is underutilized especially in the elderly.
Although elderly patients are at increased risk of
hemorrhage with oral anticoagulants, the
benefit for ischemic stroke reduction exceeds
the risk of hemorrhage for most elderly patients.
Consequently, age alone should not be
considered a contraindication for anticoagulation.
Novel oral anticoagulants such as dabigatran,
rivaroxaban and apixaban are at least as effective
as warfarin in preventing strokes in patients
with AF. Relative to warfarin, these novel agents
reduce the risk of intracranial hemorrhage,
the most devastating complication of
anticoagulation therapy in elderly AF patients.
The novel oral anticoagulants are especially
appealing for stroke prevention in elderly
patients with AF.
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INTRODUCTION
Atrial fibrillation (AF) is a major risk factor for
disabling ischemic stroke due to embolism from
the left atrial appendage. The prevalence of AF
increases with increasing age (Fig. 1) [1]. The
true prevalence of AF is difficult to assess, as
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a significant proportion of patients will be
asymptomatic or have subclinical disease;
however, it is estimated that at least 10% of
elderly people (C75 years old) have AF [2] and
56% of people with the condition are elderly [3,
4]. The influence of AF on health increases with
age, and 71% of strokes that occur in patients
with AF are in those aged over 70 years [5]. The
outcome of patients following stroke due to AF
is worse, on average, compared with non-AF-
related strokes [6].
Antiplatelet agents and oral anticoagulants
are effective in reducing the risk of stroke
in AF patients, with oral anticoagulants
being more effective in reducing the risk of
ischemic strokes than antiplatelet agents [7].
However, increasing age is associated with
underutilization of warfarin [8]. Clinical data
on elderly patients are limited as they are often
underrepresented in randomized controlled
trials (RCTs). Furthermore, older patients have
an increased risk of hemorrhage and often have
multiple comorbidities including chronic
kidney disease (CKD), anemia, hypertension,
diabetes and an increased risk of falls.
In recent years, novel selective oral
anticoagulants have become available. All
undergo substantial renal excretion [9], but are
at least as effective as adjusted-dose warfarin in
reducing the risk of stroke. They are also
associated with a decreased risk of intracranial
hemorrhage in patients with AF [10–12]. While
it is likely that the new generation of novel oral
anticoagulants will eventually replace warfarin,
the role of these agents in the elderly remains to
be fully defined. This review examines the use of
novel oral anticoagulants in patients aged
C75 years with AF, focusing on information
from randomized trials. In addition, the
relationship between age, AF and stroke risk,
as well as the current evidence for oral
anticoagulants and antiplatelet agents for
stroke prevention in the elderly, will be
considered.
Fig. 1 Prevalence of AF with increasing age [1]. Error bars indicate 95% conﬁdence intervals. Numbers indicate number of
men and women with atrial ﬁbrillation in each category. Adapted from Go et al. [1]
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METHODS
This review article incorporates data from
observational studies, review articles, available
guidelines and RCTs on the use of anticoagulants
and antiplatelet agents for stroke prevention in
elderly patients. Relevant literature was obtained
with a MEDLINE search. The literaturewas chosen




AF is the most common clinically significant
arrhythmia and is associated with significant
mortality and morbidity [13]. The number of
patients with AF is forecast to increase as will
the proportion of elderly patients [1]. Adjusting
for age, risk factors for AF include valvular heart
disease, congestive heart failure, diabetes and
hypertension, all of which are more common in
the elderly.
AF independently increases stroke risk
by fivefold in the general population and
accounts for a greater proportion of strokes
with increasing age [5]. The risk of
thromboembolism in AF increases sharply
with age over 65 years, with the relative risk
increasing approximately 1.45-fold per decade
[7]. Age is a strong and consistent predictor of
stroke in patients with AF and is included in all
stroke risk stratification schemes for AF [14, 15].
While increasing age as a risk factor for AF and
stroke is continuous, age C75 years is arbitrarily
used to dichotomize risk in cohort analyses and
systematic reviews [16].
Other independent risk factors for stroke
include previous transient ischemic attacks or
stroke, heart failure, hypertension and diabetes.
The Congestive cardiac failure, Hypertension,
Age C75, Diabetes and previous Stroke or
transient ischemic attack (CHADS2) score is a
simple, commonly used stroke risk stratification
scheme for patients with AF [17]. It was
developed by incorporating the Stroke
Prevention in AF (SPAF) and AF Investigators
(AFI) risk schemes and was validated in a cohort
of patients with AF admitted to hospital [18–20]
(Table 1). Most guidelines now recommend the
use of vitamin K antagonists in patients with a
CHADS2 score of 1 or greater. However, the
recommendations have to be balanced against
the risk of hemorrhage, which is higher during
anticoagulation in the elderly.
Table 1 Comparison of CHADS2 and HAS-BLED
scores [18–20]





Hypertension 1 Stroke 1
Age[75 years 1 Bleeding history 1
Diabetes 1 Labile INRs 1
Previous stroke 2 Drugs or ethanol
abuse
1 each









0 1.9 0 1.13
1 2.8 1 1.02
2 4.0 2 1.88
3 5.9 3 3.74
4 8.5 4 8.70
5 12.50 5 12.50
6 18.2 6–9 [12.5
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The Congestive cardiac failure, Hypertension,
Age C75, Diabetes and previous Stroke or
transient ischemic attack, Vascular disease, Age
65–74 and Sex score (CHA2DS2-VASc) has been
proposed as an improvement over CHADS2,
specifically for stratifying risk in patients under
the age of 75 years, who do not have any of the
CHADS2 risk factors for stroke [21, 22]. In
addition to the risk factors identified in the
CHADS2 score, CHA2DS2-VASc incorporates one
point each for sex, history of vascular disease
and age C65 years. Age C75 years will incur an
extra point.
Female sex is incorporated into CHA2DS2-
VASc as an independent predictor of stroke in
AF despite the absence of a clear biologically
plausible explanation for the underlying
etiology. Large differences in stroke risk
between the sexes were noted in the AFI meta-
analysis in 1990 [23] and were consistent
with large observational studies [24–26]. The
difference in stroke risk between the sexes was
greatest with increasing age. Elderly women had
a significantly higher risk of stroke compared
with similarly aged men [24].
The additional components within
CHA2DS2-VASc compared with CHADS2 was
shown to improve discrimination in patients
with a CHADS2 score of 1 by identifying
patients aged \75 years with sufficiently low
absolute stroke risk who may not be expected to
benefit from anticoagulant therapy [15, 22]
(Fig. 2). Conversely, all patients aged C75 years
would be considered for anticoagulation, as the
additional point for older age would give a
CHA2DS2-VASc score of at least 2 [27, 28].
Renal function declines gradually with age
and CKD is common in patients with AF. One-
third of all outpatients with AF and over 50%
of elderly patients with AF have CKD
(estimated glomerular filtration rate (eGFR)
\60 ml/min) [29, 30]. CKD is an independent
predictor of stroke risk in patients with AF (HR
1.5) [29, 31, 32] and the impact of Stage 3 CKD
on stroke risk is similar to other predictors used
in the CHADS2 score [14]. However, the precise
mechanisms underlying increased stroke risk
in CKD are unclear and have not been
incorporated into any of the commonly used
risk stratification scores. There are less data
stratifying stroke risk in Stage 4 CKD and end
stage renal failure, but AF remains an
independent risk factor for ischemic stroke
[33].
Fig. 2 Comparative rate of death, stroke and systemic embolism between CHADS2 versus CHA2DS2-VASc [15, 22]
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Warfarin in Elderly Patients with AF
Most ischemic strokes in patients with AF are
due to cardiogenic embolism from thrombi
originating from the left atrial appendage;
however, up to 25% of cases may be caused by
intrinsic small vessel cerebrovascular disease
with co-existing vascular risk factors such as
coronary artery disease, hypertension and
diabetes [34]. Aspirin appears to exert most of
its effect via prevention of non-cardiogenic
embolic events, while warfarin is far superior
to aspirin in preventing cardio-embolic
ischemic strokes [34]. At most, aspirin reduces
the relative risk of stroke by about 25% in
patients with AF. Most of the reduction in
stroke risk with aspirin leads to a reduction in
transient ischemic attacks and non-disabling
strokes [35]. Dose-adjusted warfarin reduces the
relative risk of stroke by about 60% in patients
with AF compared with placebo [3, 28, 36].
With increasing age, the benefit of aspirin in
preventing stroke decreases and appears to be
ineffectual when patients enter their eighth
decade, whereas the risk reduction derived from
warfarin anticoagulation is preserved with age
[7].
The most serious side effect of warfarin is
bleeding, including intracranial bleeding. Age is
an independent risk factor for bleeding on
anticoagulant therapy [37, 38] and warfarin is
associated with an increased risk of bleeding
compared with aspirin therapy (HR 1.71) [39].
The absolute risk reduction of all strokes and
cardiovascular events is not substantially offset
by the proportionally smaller increased risk of
hemorrhage in the general population. Elderly
patients are likely to derive the greatest benefit
from warfarin therapy, but have the highest
risk of hemorrhage. Elderly patients are
underrepresented in most RCTs assessing the
use of warfarin in AF, with patients aged
C75 years representing only 20% of patients in
most RCTs involving oral anticoagulants in AF
[40]. The exception is the Birmingham AF
Trial in the Aged (BAFTA), which was
restricted to AF patients C75 years old with no
contraindications to hemorrhage. BAFTA
participants were randomized to warfarin
versus aspirin, and there was no increased risk
of major hemorrhage with anticoagulation. The
rates of hemorrhage in BAFTA were lower when
compared with a previous subgroup meta-
analysis of anticoagulation in patients aged
C75 years. 40% of patients in BAFTA had
already been established on warfarin and
probably underestimated bleeding risk
compared with warfarin-naı¨ve patients [41].
Prediction of Hemorrhage in Elderly
Patients on Warfarin
Several risk stratification scores have been
developed to help predict hemorrhage during
warfarin anticoagulation. The Hypertension,
Abnormal liver/renal function, Stroke,
Bleeding history or disposition, Labile
International Normalized Ratio, Elderly,
Drugs/alcohol (HAS-BLED) score has been
incorporated in European and Canadian
guidelines on the management of patients
with AF [19, 20]. The score is relatively easy to
use and provided modest predictive value for
major hemorrhage in patients on oral
anticoagulants (C-statistic 0.69) in the Euro
Heart Survey cohort [42]. However, HAS-BLED
requires validation in other patient populations
such as the elderly before it is adopted
universally. Other bleeding risk prediction
scores for warfarin anticoagulation have been
proposed, but none have been adequately
validated in our view [38, 43]. Many of the
factors that predict hemorrhage in these risk
prediction scores are also risk factors for stroke.
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Therefore, the use of risk stratification scores in
elderly patients with AF is likely to be limited as
a result (Table 1).
Based on CHA2DS2-VASc risk factors, men
with no hypertension, diabetes or prior stroke
but who had AF in the SPAF trials were at the
lowest risk of stroke while on aspirin therapy,
with a stroke rate of 1.6%/year (95% CI 0.7–3.9)
[7]. Men aged C75 years participating in BAFTA
and without other CHA2DS2-VASc risk factors
had a stroke rate of 2.1%/year (95% CI 0.77–4.6)
during aspirin therapy [27]. The margin of error
for these rates is wide and includes rates that
would warrant anticoagulation. Elderly women
with AF carry a higher risk of stroke than elderly
men [28]. It is unclear whether patients aged
C75 years with AF who are at low risk can be
reliably identified.
Randomized Trials Comparing Warfarin
Versus Aspirin in Patients with AF Aged
‡75 years
A meta-analysis of randomized trials, including
29 trials involving 28,044 patients with a mean
age of 71 years, confirmed the superiority of
warfarin over anti-platelet agents in reducing
stroke risk. The absolute increase in major
extracranial hemorrhage on warfarin compared
with aspirin was overshadowed by the absolute
reduction in stroke risk in patients with AF [44].
However, only 2,680 (10%) participants in these
randomized trials were C75 years old despite the
fact that most patients with AF were within this
age group. However, based on the AFI pooled
meta-analysis from six trials [39] and the
results of BAFTA [45], it is clear that warfarin
anticoagulation reduces the risk of stroke to a
greater extent than aspirin in elderly patients with
AF (Table 2) [46, 47].
In BAFTA, elderly patients on oral
anticoagulants had a 52% relative risk
reduction in all strokes or systemic embolism
compared with aspirin and had no significant
increase in intracranial or extracranial
hemorrhage [45]. The risk of major
hemorrhage was lower than that noted in the
AFI pooled meta-analysis [39]. This may be
explained by the use of a contemporary
International Normalized Ratio (INR) target
range of 2–3. In addition, 40% of patients in
BAFTA were not warfarin naı¨ve and were
already established on warfarin prior to
enrollment compared with the warfarin-naı¨ve
Table 2 Absolute stroke rate in AF patients C75 years old and effect of anticoagulation







AF Investigators (2002) [39] 855 5.9%/yeara Warfarin 0.37# 46
BAFTA (2007) [45] 485 4.9%/year Warfarin 0.52# 40
ACTIVE A (2009) [46] *1,550 4.4%/year NA NA NA
AVERROES (2011) [47] *950 6.1%/year Apixaban 0.67# 24
N number of participants, NNT number needed to treat, NA not applicable
In addition, the observational cohort ATRIA study reported an ischemic stroke rate of 3.2%/year among 2,313 AF patients
C75 years who were not taking warfarin [1]
a Restricted to ischemic strokes
# Statistically signiﬁcant reduction with p value\0.05
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cohorts in the other studies included in the AFI
pooled meta-analysis. This observation is
supported by other recent warfarin inception
studies in which elderly patients had an
increased risk of hemorrhage in the first year
of treatment [41, 48]. Once established on
treatment and monitored closely, warfarin is
safe in elderly patients with AF.
Current guidelines support the use of oral
anticoagulation therapy in all patients
C75 years for the prevention of ischemic
stroke [3, 28]. Despite this, the uptake of oral
anticoagulants among patients C75 years
remains low. In our view, all patients with AF
C75 years old (and especially women) should be
considered for anticoagulation prophylaxis to
prevent stroke in the absence of any clear
contraindications, provided it can be initiated
and monitored safely [7]. From the data
summarized above, the risk of stroke for these
patients is sufficiently high and the efficacy of
warfarin is established.
Challenges with Warfarin Anticoagulation
in Elderly Patients with AF
While all patients aged C75 years should be
considered for warfarin anticoagulation, the
decision to prescribe warfarin for an individual
patient should take into consideration risk of
stroke versus hemorrhage, practicalities for
monitoring anticoagulation and patient
preference [49, 50]. Furthermore, patients with
AF aged C75 years are more likely to experience
significant co-morbidities on multiple
medications.
Time in Therapeutic Range on Warfarin
Anticoagulation
Limitations of vitamin K antagonists for stroke
prevention include their narrow therapeutic
window, which requires regular blood
monitoring for assessment of INR and dosage
adjustments. The optimal therapeutic range for
anticoagulation with warfarin in non-valvular
AF is between 2 and 3. Higher intensity
anticoagulation with INRs of greater than 3
are associated with double the risk of
intracranial hemorrhage compared with
patients who are not on warfarin [51–53]. The
risk of intra-cerebral hemorrhage is higher with
advancing age [54]. Conversely, a target INR of
less than 2 confers no further reduction in
hemorrhage risk compared with an INR of 2–3
[52]. Attaining an INR[2 is associated with not
just lower risk of stroke, but also reduced stroke
severity and fewer deaths [51].
Older patients are more sensitive to warfarin
and require lower dosages to achieve a target
INR range [55]. In addition, older patients are
more likely to be on multiple medications with
frequent INR fluctuations due to ill health, poor
diet and issues with compliance, which may
ultimately result in less time within the
therapeutic INR range compared with younger
patients. Closer monitoring of anticoagulation
may be merited in elderly patents. The highest
risk of major bleeding during warfarin
anticoagulation is in the first 12 months after
treatment initiation. Subsequently, warfarin-
experienced patients are at lower risk of
hemorrhage and stroke compared with
warfarin-naı¨ve patients [45].
Risk of Falls
Other risk factors for intracranial hemorrhage in
the elderly are an increased risk of falls and
associated neuropsychiatric disease [38, 56].
Risk of falls and intra-cerebral hemorrhage
with warfarin are often quoted as a reason to
avoid anticoagulation. However, if a patient has
a 5% annual risk of stroke from AF, it has been
estimated that the patient would need to fall
over 295 times to offset the benefit of oral
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anticoagulants [57]. The association between
intracranial hemorrhage and neuropsychiatric
disease is multifactorial in nature and may be
more a reflection of impairment of functional
status. Psychotropic medications, poor
compliance with medication and associated
alcohol use may all contribute to the increased
risk of falls in patients with neuropsychiatric
disease. Patients with Alzheimer’s dementia
may be predisposed to intracranial
hemorrhage if they have amyloid angiopathy
or apolipoprotein E polymorphisms. However,
quantification of the risk and application to
decision-making regarding anticoagulation in
this setting have not been clearly defined.
Chronic Kidney Disease and Anemia
The prevalence of renal disease increases with
advancing age [30]. Patients with CKD have
three times the risk of AF compared with patients
without CKD and are likely to be on warfarin
anticoagulation. However, stage 3 CKD is
associated with twice the rate of major bleeding
during warfarin anticoagulation [12, 58]. These
higher rates of major bleeding were not adjusted
for age. In a longitudinal cohort analysis, stage 3
CKD was not an independent predictor of
hemorrhage during warfarin anticoagulation
[59]. While the Anticoagulation and Risk
Factors In AF (ATRIA) dataset showed CKD with
an estimated creatinine clearance (eCrCl) of
\30 ml/min was an independent predictor of
major hemorrhage (HR 4.3, p\0.001), it has not
been sufficiently validated for general clinical use
[43]. Whist patients with CKD are at increased
risk of anemia, the same ATRIA dataset
concluded anemia (hemoglobin \13 g/dl in
men; \12 g/dl in women) was an independent
predictor of hemorrhage (HR 4.2, p\0.001) [43].
Anemia is prevalent in the elderly and is
estimated to affect 23.9% of patients over the
age of 70 years [60, 61].
Patient Preferences for Anticoagulation
The decision to take anticoagulation for AF
requires consideration of the potential risks and
benefits. Physicians and patients can differ in
how they weigh up these factors when arriving
at a decision to take oral anticoagulants.
Patients at risk of developing AF, who have no
previous history of stroke, place more value on
the avoidance of stroke and less value on the
avoidance of bleeding than physicians [62].
There is significant underuse of
antithrombotic drugs in elderly patients
with AF. Physicians may make strong
recommendations for or against warfarin as a
treatment, but patient preferences should be
considered before making decisions about
anticoagulation.
Novel Selective Oral Anticoagulants
for Elderly Patients with AF
While warfarin has been established as the
mainstay treatment for SPAF, novel
anticoagulants have been introduced in the
past few years, which are more selective in
their anticoagulant mechanisms and easier to
administer. Four novel anticoagulants (two
direct thrombin inhibitors, ximelagatran and
dabigatran, and two factor Xa inhibitors,
apixaban and rivaroxaban) have been
evaluated in large phase III randomized trials.
Ximelagatran was withdrawn from the market
in 2006 due to rare, but serious, hepatotoxicity.
The other novel anticoagulants have not shown
the same adverse effect. The four recent
randomized trials testing the novel oral
anticoagulants in AF patients included 21,062
participants C75 years old and provide
substantial evidence for their efficacy in this
age group [10–12, 47] (Table 3).
Dabigatran, apixaban and rivaroxaban do
not require regular anticoagulation monitoring
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or frequent dose adjustments; however, a
specific antidote to rapidly reverse the
anticoagulant effect of these agents in the
event of an acute hemorrhage is not available
(other than acute hemodialysis for agents such
as dabigatran) [63] (Table 4). These novel
anticoagulant agents have been approved for
clinical use and have been shown to be at least
non-inferior to dose-adjusted warfarin for stroke
prevention.
Table 3 Comparison of novel oral anticoagulants in patients C75 years
Novel
agent











Dabigatran RE-LY [10] Dabigatran 110 mg bid 7,258 0.88 (0.66–1.17) 1.01 (0.83–1.23)
Dabigatran 150 mg bid 0.67 (0.49–0.90) 1.18 (0.98–1.42)
Rivaroxaban ROCKET-AF
[11]
Rivaroxaban 20 mg bid (15 mg
od if eCrCl 30–49 ml/min)
6,229 0.88 (0.75–1.03)a 1.04 (0.90–1.20)a
Apixaban ARISTOTLE
[12]
Apixaban 5 mg bid 5,678 0.79 (0.65–0.95)b 0.69 (0.60–0.80)b
AVERROES
[47]
Apixaban 5 mg bid (2.5 mg bid if
2 out of 3 of the following criteria;
serum creatinine C133 ml/min, age
C80 years or weight B60 kg) vs.
Aspirin
1,897 0.46 (0.33–0.65)b 1.13 (0.74–1.75)b
a Intention to treat analysis. Estimated from the entire group irrespective of age as no statistically signiﬁcant interaction
with age
b Estimated from the entire group irrespective of age as no statistically signiﬁcant interaction with age
Table 4 Key pharmacological characteristics of novel anticoagulants
Feature Drug
Dabigatran Rivaroxaban Apixaban
Type of drug Direct thrombin inhibitor Factor Xa inhibitor Factor Xa inhibitor
Half-life (h) 14–17 7–11 8–15




Dosage 150 mg bid (110 mg bid if
patients at risk of bleeding or
[80 years of age)
20 mg od (15 mg od in
patients with eCrCl
15–49 ml/min)
5 mg bid (2.5 mg bid in patients with
impaired renal function and[80 years
or\60 kg in weight
Age-related dosage
recommendations
110 mg bid if[80 years None 2.5 mg bid if[80 years with serum
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Dabigatran
In the Randomized Evaluation of Long-term
Anticoagulant TherapY (RE-LY) randomized
trial, two doses of dabigatran (110 mg and
150 mg twice daily) were compared with
warfarin [10]. Both doses of dabigatran in RE-
LY were associated with a lower risk of major
hemorrhage in patients \75 years, but this was
not the case in those aged C75 years. The risk of
major hemorrhage and extracranial
hemorrhage rose more steeply with dabigatran
than warfarin with increasing age. Dabigatran
150 mg twice daily was associated with an
increased risk of major extracranial bleeding in
elderly patients compared with warfarin.
However, the risk of intracranial bleeding
remained lower with both doses of dabigatran
with no evidence of interaction with age [64].
Dabigatran 150 mg bid was associated with a
lower risk of strokes or systemic embolism
compared to warfarin and there was no
association between dabigatran and the risk of
myocardial infarctions [10]. As dabigatran is
dependent on renal excretion, it is
contraindicated in severe renal disease (eCrCl
\30 ml/min). In the USA, only dabigatran
150 mg bid is licensed for use in the
prevention of strokes in patients with AF,
while in Canada and the UK dabigatran
110 mg bid is also licensed for use in patients
at increased risk of bleeding (older patients
[80 years, eCrCl 30–60 ml/min or low body
weight).
Rivaroxaban
In contrast to the other novel anticoagulants
currently on the market, rivaroxaban is dosed
daily (Table 4). Rivaroxaban is less dependent
on renal excretion compared with dabigatran.
Rivaroxaban was compared with warfarin in the
Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with vitamin K
Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET-
AF) study in patients at high risk of stroke and
hemorrhage [11]. While patients with severe
renal disease were excluded from the trial,
patients with moderate renal function (eCrCl
30–49 ml/min) were recruited and received a
reduced dose of rivaroxaban (15 mg daily).
There was no significant difference in stroke or
systemic embolism on comparing the treatment
effects of rivaroxaban versus warfarin in
patients with or without reduced eCrCl [58].
The risk of intracerebral and fatal hemorrhages
was lower with rivaroxaban compared with
warfarin. However, there was an increased risk
of non-major clinically relevant bleeding in
patients aged C75 years treated with
rivaroxaban compared with warfarin [65].
Apixaban
Apixaban was compared with warfarin in the
Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE) study [12] and with aspirin in
patients deemed intolerant of warfarin in the
Apixaban Versus Acetylsalicylic Acid to Prevent
Stroke in Atrial Fibrillation Patients Who Have
Failed or Are Unsuitable for vitamin K
Antagonist Treatment (AVERROES) study [47].
The dose of apixaban was reduced from 5 mg
bid to 2.5 mg bid in participants who had a
serum creatinine concentration B1.5 mg/dl
(133 lmol/l) and either age C80 years or a
body weight B60 kg in both studies. When
compared against warfarin, apixaban was more
effective in reducing strokes and all-cause
mortality and had a lower risk of major
bleeding with no significant age interaction
[12]. Those participants with at least moderate
renal impairment (eCrCl 25–50 ml/min) had
half the rate of major hemorrhage with
apixaban (3.3%) versus warfarin (6.7%) [66].
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When compared with aspirin in patients
deemed unsuitable for warfarin in the
AVERROES study, apixaban was superior to
aspirin in preventing stroke or systemic
embolism in patients with AF, including those
aged C75 years [47]. There was no significant
increase in risk of major bleeding in patients
C75 years. In addition, there was no significant
difference in the risk of major bleeding in
patients with stage 3 CKD. The results of the
AVERROES study have significant implications
for at least 30% of patients who are considered
ideal candidates for anticoagulation therapy
and are at risk of stroke, but are not on
warfarin [67]. This is particularly relevant in
the elderly as over 50% of patients C75 years
who are at risk of strokes due to AF are not on
anticoagulation therapy [26, 48].
Comparisons Between Novel Oral
Anticoagulants
The use of novel anticoagulants to reduce stroke
risk in patients remains an exciting avenue for
further study. The differences in trial
populations between individual trials with
differing dosing regimens and lack of head-to-
head comparisons combine to prevent reliable
comparisons between novel agents. Indirect
comparisons may be misleading, as the
populations were not homogenous. ROCKET-
AF included a population at high risk of stroke
compared with the RE-LY and ARISTOTLE
studies. In addition, the time in therapeutic
range achieved in the warfarin arm of the
ROCKET-AF study was lower than in RE-LY
and ARISTOTLE. Aspirin use could have affected
the safety and efficacy of the novel agents and
was lowest in ARISTOTLE (30.9%) [12] (vs.
39.7% in RE-LY (39.7%) [10] and 36.5% in
ROCKET-AF [11]).
Based on our analysis of available evidence,
apixaban (ARISTOTLE dosing schedule),
rivaroxaban (ROCKET-AF dosing schedule) and
dabigatran 150 mg bid are all superior to
therapeutic warfarin anticoagulation for
reduction in stroke and systemic embolism in
patients with AF C75 years old. The relative risk
reduction for stroke or systemic embolism with
these new oral anticoagulants averages about
30%. This translates to a number needed to treat
of about 150 elderly AF patients per year to
prevent one stroke or systemic embolism with
novel anticoagulants compared with warfarin.
Major hemorrhage rates are similar or reduced
by novel oral anticoagulants compared with
warfarin in elderly AF patients; an exception to
this is high-dose dabigatran, which is associated
with a major increase in gastrointestinal
bleeding, but a significant reduction in
intracranial hemorrhage relative to warfarin.
CONCLUSIONS
The prevalence and importance of AF is
increasing with an aging population. Oral
anticoagulants are effective at reducing the
absolute risk of ischemic stroke compared with
antiplatelet agents in elderly patients, but are
associated with increased risk of hemorrhage.
However, the risk of extracranial hemorrhage is
overshadowed by the absolute reduction in risk
of stroke in most elderly patients. Novel
anticoagulants, dabigatran, rivaroxaban and
apixaban, are at least as effective as warfarin in
reducing the risk of stroke and are safer in
elderly patients than warfarin. These agents are
also easier to use and unlike warfarin do not
require frequent blood test monitoring. The use
of novel anticoagulant agents will likely
increase as these agents are better tolerated
than warfarin in the elderly. While more
Cardiol Ther (2013) 2:135–149 145
123
expensive compared with warfarin, the absolute
economic costs remain uncertain. The greater
use of anticoagulation with either warfarin or
these novel agents will reduce the risk of
ischemic stroke in elderly patients. As more
novel anticoagulants such as edoxaban come to
market, direct randomized comparisons of the
novel agents will be necessary to delineate clear
roles for the individual agents. Currently, recent
trials of novel anticoagulants have challenged
whether warfarin should be the preferred
anticoagulant option for elderly patients. The
novel anticoagulants are clearly effective for use
in elderly patients with AF in clinical trials and
should be strongly considered when
anticoagulation is indicated.
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